These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3562900)

  • 21. Inhibition of satiety by a cholecystokinin antagonist is independent of gastric emptying.
    Collins SM; Weingarten HP
    Peptides; 1984; 5(3):481-4. PubMed ID: 6089141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unsulfated CCK-8 not blocked by proglumide or CR 1409 in the mouse abdominal irritant-induced stretching assay: possible central site of action.
    Ambrose FG; Barbaz BS; Autry WL; Browne RG; Liebman JM
    Peptides; 1989; 10(1):31-4. PubMed ID: 2748423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential effects of sulfated cholecystokinin octapeptide and proglumide injected intrathecally on antinociception induced by beta-endorphin and morphine administered intracerebroventricularly in mice.
    Suh HH; Tseng LF
    Eur J Pharmacol; 1990 Apr; 179(3):329-38. PubMed ID: 2142090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antagonists of central and peripheral behavioral actions of cholecystokinin octapeptide.
    Crawley JN; Stivers JA; Hommer DW; Skirboll LR; Paul SM
    J Pharmacol Exp Ther; 1986 Feb; 236(2):320-30. PubMed ID: 3003339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potentiation of beta-endorphin effects by proglumide in rats.
    Katsuura G; Itoh S
    Eur J Pharmacol; 1985 Jan; 107(3):363-6. PubMed ID: 3156751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential antagonism by proglumide of various CCK-mediated effects in mice.
    Barbaz BS; Autry WL; Ambrose FG; Gerber R; Liebman JM
    Prog Clin Biol Res; 1985; 192():151-8. PubMed ID: 4080708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological characterisation of a new potent and specific nonpolypeptidic cholecystokinin antagonist.
    Setnikar I; Bani M; Cereda R; Chisté R; Makovec F; Pacini MA; Revel L; Rovati LC; Rovati LA
    Arzneimittelforschung; 1987 Jun; 37(6):703-7. PubMed ID: 3663268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists.
    Makovec F; Bani M; Cereda R; Chisté R; Pacini MA; Revel L; Rovati LA; Rovati LC; Setnikar I
    Arzneimittelforschung; 1987 Nov; 37(11):1265-8. PubMed ID: 3440035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cholecystokinin-8 and proglumide modulation of electrically elicited eating.
    Schneider LH
    Prog Clin Biol Res; 1985; 192():123-30. PubMed ID: 4080705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of effects of proglumide and CR 1409, a new glutaramic acid derivative, on CCK-8-induced pancreatic polypeptide and insulin secretion in the dog.
    Inui A; Oya M; Inoue T; Sakatani N; Morioka H; Baba S
    Horm Metab Res; 1988 Jan; 20(1):61-2. PubMed ID: 3286447
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of the novel cholecystokinin receptor antagonist CR-1392 on cholecystokinin-induced antroduodenal and pyloric motor activity in vivo.
    Allescher HD; Daniel EE; Fox JE; Kostolanska F; Rovati LA
    J Pharmacol Exp Ther; 1989 Dec; 251(3):1134-41. PubMed ID: 2600808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proglumide (gastrin and cholecystokinin receptor antagonist) inhibits insulin secretion in vitro.
    Verspohl EJ; Wunderle G; Ammon HP; Williams JA; Goldfine ID
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Mar; 332(3):284-7. PubMed ID: 3012373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cholecystokinin and cholecystokinin antagonists enhance postsynaptic excitability in the dentate gyrus.
    Sinton CM
    Peptides; 1988; 9(5):1049-53. PubMed ID: 3244557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two proglumide analogues are equipotent antagonists of the inhibition of food intake by CCK-8.
    Schneider LH; Murphy RB; Smith GP
    Peptides; 1988; 9 Suppl 1():207-14. PubMed ID: 2856646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic administration of cholecystokinin (CCK) inhibits operant water intake in rats: implications for the CCK-satiety hypothesis.
    Ebenezer IS
    Proc Biol Sci; 1996 Apr; 263(1369):491-6. PubMed ID: 8637930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma concentrations of cholecystokinin octapeptide and food intake in male rats treated with cholecystokinin octapeptide.
    Lindén A; Uvnäs-Moberg K; Forsberg G; Bednar I; Södersten P
    J Endocrinol; 1989 Apr; 121(1):59-65. PubMed ID: 2565947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives.
    Makovec F; Peris W; Revel L; Giovanetti R; Mennuni L; Rovati LC
    J Med Chem; 1992 Jan; 35(1):28-38. PubMed ID: 1732532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cholecystokinin octapeptide, proglumide, and passive avoidance in rats.
    Deupree D; Hsiao S
    Peptides; 1987; 8(1):25-8. PubMed ID: 3575151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proglumide analogues: potent cholecystokinin receptor antagonists.
    Jensen RT; Murphy RB; Trampota M; Schneider LH; Jones SW; Howard JM; Gardner JD
    Am J Physiol; 1985 Aug; 249(2 Pt 1):G214-20. PubMed ID: 2411147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of cholecystokinin in the regulation of satiation and satiety in humans.
    Lieverse RJ; Jansen JB; Masclee AA; Lamers CB
    Ann N Y Acad Sci; 1994 Mar; 713():268-72. PubMed ID: 8185168
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.